InferMed appoints Cancer Research UK's Dr Sally Burtles as Observer to the Board

InferMed, a leading provider of advanced software solutions for clinical research and practice, has appointed Dr Sally Burtles, Director of Drug Development at Cancer Research UK, as an Observer to the Board.

InferMed has a long-standing relationship with Cancer Research UK, and was backed by the charity at its formation in 1999. A research relationship continues with Cancer Research UK, which remains InferMed's largest institutional shareholder.

Dr Burtles has fifteen years' experience on the Drug Development team at Cancer Research UK, the world's leading independent organisation dedicated to cancer research. In her current position as Director of Drug Development, Dr Burtles is responsible for the strategic planning and operation of Cancer Research UK's new drug evaluation programme.

Dr Burtles previously held the roles of Assistant Director of Drug Development, and Acting Assistant Director of Drug Development (Clinical). She has also been an Invited Visiting Fellow for the National Cancer Institute (NCI) at the USA Food and Drug Administration (FDA).

Prior to joining Cancer Research UK, Dr Burtles was a post-doctoral research scientist at Sandoz AG in Basel. Dr Burtles graduated with a BSc in Biochemistry from the University of St Andrews, Scotland and went on to gain a RT Jones Scholarship to Emory University, Atlanta, Georgia, and then to study for a PhD in Immunology at Bristol University, Bristol, UK.

Commenting on the appointment, Duane Lawrence, CEO of InferMed, said: "With her experience and knowledge of the drug development arena, Dr Burtles will add important insight and perspective to our strategy decisions. We are delighted to welcome her as an Observer to the Board at this important stage in InferMed's development and growth."

About InferMed
InferMed Ltd is a provider of advanced software solutions for clinical research and practice. The Company was founded in 1999, as a spinout from the Imperial Cancer Research Fund's (now Cancer Research UK) Advanced Computational Laboratory, with the mission to commercialise highly advanced software technology developed for clinical research and practice. InferMed's products are currently used across healthcare, pharmaceutical and clinical research sectors worldwide.

InferMed's lead products, MACRO and Arezzo were developed from work started at Cancer Research UK. MACRO supports clinical trials, helping with the collection of data and the management of trial protocols, and is currently being used for over 85,000 patients at more than 400 sites in 36 countries worldwide. Arezzo is highly advanced clinical decision support software designed to aid clinicians through the process of diagnosis and treatment. Arezzo provides active clinical guidelines and protocols at the point-of-care, reducing the risk of misdiagnosis and improving treatment for patients.

Website: www.infermed.com

Most Popular Now

AstraZeneca enters license agreement with KYM Bios…

AstraZeneca and KYM Biosciences Inc.* have entered into a global exclusive licence agreement for CMG901, a potential first-in-class antibody drug conjugate (ADC) targetin...

Pill for skin disease also curbs excessive drinkin…

Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an "incredibly promi...

Pfizer's elranatamab receives FDA and EMA filing a…

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the company's Biologics License Application (BLA) ...

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

Digital twin opens way to effective treatment of i…

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently...

AI conjures proteins that speed up chemical reacti…

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in...